Background: Patients receiving insulin or certain oral hypoglycemic agents are at increased risk for hypoglycemia, which results in more than 100 000 emergency department visits incurring approximately $120 million in costs annually (1) . Although not all of these visits can be prevented, glucagon use could reduce the number and severity of hypoglycemic episodes requiring emergency medical attention and hospitalization. Data from the National EMS Information System's public-release research data sets (2) between 2013 and 2015 and from Medicare Part D (3) claims from 2014 suggest that glucagon is underutilized in the prehospital setting and underprescribed in the outpatient setting. Despite its effectiveness, it is not allowed to be administered by most emergency medical services (EMS) personnel; however, family members do so routinely.
Objective: To understand glucagon use and availability in the prehospital and outpatient setting.
Methods: We included cases from the National EMS Information System in which glucagon was administered. Response times longer than 60 minutes were eliminated as probable errors. Medicare Part D data from 2014 were filtered, retaining only those cases in which glucagon was prescribed. State EMS offices were contacted to review protocols for glucagon administration and blood glucose testing. Data from the National EMS Information System between 2013 and 2015 and from the Centers for Medicare & Medicaid Services data warehouse were analyzed in Alteryx, version 11 (Alteryx), and Tableau, version 10.2.1 (Tableau Software).
Findings: Across all states, glucagon was administered in 89 263 cases in the prehospital setting between 2013 and 2015. Dispatchers correctly coded only 44.67% of the calls as a "diabetic problem." The patient experienced adverse effects in 3944 of the events in which glucagon was administered.
In most states, paramedics are the only members of EMS who carry and administer glucagon (Figure) . However, nationally there are 198 200 providers of basic emergency medicine compared with 61 121 paramedics; therefore, the dispatched responder may be unable to treat hypoglycemia with glucagon 3 out of 4 times (4). The mean EMS response time to calls in which glucagon was administered was 15.34 minutes (SD, 11.50).
Hypoglycemia is a substantial burden on the health care system. Among persons aged 65 years or older, hypoglycemic events occur at an estimated rate of 5.01 per 100 personyears (5). Inpatient admissions for hypoglycemia cost an average of $18 961, and emergency department visits cost an average of $1487 (both adjusted for inflation). The total cost to Medicare Part D for glucagon prescriptions was $5 044 593 (adjusted for inflation) with an average cost of $212 per prescription for these 23 423 prescriptions. Approximately 11.6 million Medicare beneficiaries in 2014 had diabetes (5), yet only 0.2% were prescribed glucagon.
Discussion: Our data did not allow for precise review of crew composition; however, the lack of nationwide protocols permitting providers of basic emergency medicine, who comprise 76% of all EMS responders, to carry and use glucagon (or even to check blood glucose levels in some states) probably impedes optimal care of hypoglycemic patients. These restrictions are even more surprising given that glucagon is routinely administered by family members and adverse effects were not serious and most typically included nausea.
Emergency medical service response times to episodes of hypoglycemia are crucial in the diabetes chain of survival. The average response time of more than 15 minutes suggests that policy changes may be needed, because such a delay coupled with policies preventing basic emergency medicine providers from administering glucagon may increase patients' risk for neurologic sequelae, death, or both. Further complicating care, dispatchers correctly coded only 44.67% of calls as a "diabetic problem," potentially increasing the likelihood of dispatching providers who cannot administer this agent to patients with hypoglycemia.
Despite the favorable safety profile of glucagon, it is infrequently prescribed in the outpatient setting. The average cost to Medicare for a glucagon prescription is $212. Patients who filled glucagon prescriptions had fewer hypoglycemia- related emergency department visits, suggesting that providing this agent to patients may effectively reduce prehospital hypoglycemic complications (1) .
All emergency personnel should have access to glucagon along with training to safely administer this agent to minimize unintended treatment accidents. Ensuring access is an important opportunity to reduce morbidity, mortality, and health care costs. Diabetes specialists should work with emergency medical personnel to design curricula for the safe and effective use of glucagon nationwide. (1) is as well-grounded in empirical evidence as we are likely to get and clearly comes out in favor of what both authors have long articulated with passion and reason: the benefits of a single-payer system. Supporters of such a system have not been completely transparent about the simple truth that we cannot afford the system of health care that we would actually like to have unless we accept sacrifices that we are as yet unwilling to bear. The purported savings by creating a national or state-based single-payer system are almost certainly overstated and fraught with uncertainty. In 1965, the government's lead actuary predicted that Medicare Part A would cost $9 billion by 1990; the actual cost exceeded $66 billion. To advocate that a single-payer system can be implemented without substantial and long-term taxbased subsidies and/or limiting choice and access to services that most Americans see as a birthright is disingenuous.
The deeply difficult task of paring down the growth of entitlement programs, such as Medicare, and de facto entitlement programs, such as Medicaid-the primary drivers of the nation's fiscal woes-requires limiting access to some services, restricting choice, and using the political will and managerial skills to ensure fiscal accountability. These realities are rarely addressed by reformers and critics regardless of political persuasion, and the facts on the ground are not encouraging (for example, the U.S. Department of Veteran's Affairs). Until we accept that we cannot afford the health care that we want without starving other areas of the economy in need of investment (infrastructure and education), we will remain stuck in a fruitless argument that is fired more by passion and politics than hard truths.
Arguments that the root causes of our present dilemma come down to self-serving physicians, hospitals, employers, or private insurers-or to perfidious government, for that matter-are simplistic. In fact, it is hard to find credible and consistent villainy in this dilemma. No one wants anyone to die of lack of medical care; accusations to the contrary are counterproductive. When our political and professional leaders start promoting honest discussions on health care with Americans, just maybe we will find the goodwill and selfsacrifice necessary to solve a dilemma nearly a century old. The time is past for soft soap and wishful thinking in regards to health care. It is truth we need, not comfort. 
